Loading…
O-240 Circulating AMH molecular forms throughout pregnancy of women with PCOS and controls: a systematic longitudinal follow-up
Abstract Study question Are circulating levels of molecular forms of AMH throughout pregnancy still higher in women with PCOS than in controls? Summary answer AMH and its molecular forms decrease significantly throughout pregnancy, remaining higher in women with PCOS, without modification in the pro...
Saved in:
| Published in: | Human reproduction (Oxford) 2022-06, Vol.37 (Supplement_1) |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract
Study question
Are circulating levels of molecular forms of AMH throughout pregnancy still higher in women with PCOS than in controls?
Summary answer
AMH and its molecular forms decrease significantly throughout pregnancy, remaining higher in women with PCOS, without modification in the proportion of AMH molecular forms.
What is known already
AMH injection in late gestational mice causes a “PCOS” phenotype in the offspring’s, possibly via a gestational hyperandrogenism. AMH could therefore play a role in the heritability of PCOS in women. Circulating AMH exists in different molecular forms, cleaved (active) and uncleaved. In normal women, serum AMH decreases during pregnancy. In women with PCOS, cross-sectional or partial longitudinal studies have shown higher AMH levels in the second trimester of pregnancy and at the time of delivery in women with PCOS compared to controls. To date, no longitudinal dynamic monitoring of AMH throughout pregnancy in women with PCOS has been performed.
Study design, size, duration
Systematic prospective quarterly longitudinal monocentric comparative follow up of 30 women with PCOS and 29 controls before and during pregnancy from April 2019 to September 2021. To demonstrate a high effect size with 90% power and 5% first-species risk, it was necessary to include 23 subjects per arm. With a calculated loss of follow-up rate of 20%, 29 patients must be recruited per group.
Participants/materials, setting, methods
Women aged 18 to 43y, with a pre-conception dosage of AMH, were included during the first trimester of a singleton pregnancy. PCOS group was defined according to the modified Rotterdam criteria. In the control group, the patients had normal ovarian reserve. During the first, second and third trimester of pregnancy, all women were tested for serum AMH and its molecular forms with a Beckman automatic analyser, and for serum estradiol, LH and androgen levels.
Main results and the role of chance
Before pregnancy, patients with PCOS had higher levels of AMH (58.9 vs. 18.3pmol/L; p = |
|---|---|
| ISSN: | 0268-1161 1460-2350 |
| DOI: | 10.1093/humrep/deac106.022 |